eFFECTOR Therapeutics (NASDAQ:EFTR) versus Spruce Biosciences (NASDAQ:SPRB) Critical Survey

eFFECTOR Therapeutics (NASDAQ:EFTR) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Profitability

This table compares eFFECTOR Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eFFECTOR Therapeutics	N/A	N/A	N/A
Spruce Biosciences	N/A	-203.99%	-127.96%

Valuation and Earnings

This table compares eFFECTOR Therapeutics and Spruce Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eFFECTOR Therapeutics	N/A	N/A	-$35.81 million	($13.08)	0.00
Spruce Biosciences	$4.91 million	17.59	-$38.97 million	($51.72)	-1.22

eFFECTOR Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

eFFECTOR Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.62, suggesting that its share price is 262% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for eFFECTOR Therapeutics and Spruce Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eFFECTOR Therapeutics	0	0	0	0	0.00
Spruce Biosciences	1	3	4	0	2.38

Spruce Biosciences has a consensus price target of $170.10, indicating a potential upside of 169.83%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than eFFECTOR Therapeutics.

Institutional & Insider Ownership

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 6.9% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Spruce Biosciences beats eFFECTOR Therapeutics on 7 of the 12 factors compared between the two stocks.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.